TARGRETIN

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug TARGRETIN contains one active pharmaceutical ingredient (API):

1	Bexarotene UNII A61RXM4375 - BEXAROTENE
	Bexarotene is a synthetic compound that exerts its biological action through selective binding and activation of the three RXRs: α, β, and γ. Once activated, these receptors function as transcription factors that regulate processes such as cellular differentiation and proliferation, apoptosis, and insulin sensitisation. The exact mechanism of action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.
	Read more about Bexarotene

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
Targretin Capsules	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
TARGRETIN Soft capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XF03	Bexarotene	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XF Retinoids for cancer treatment
Discover more medicines within L01XF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1196984
ES	Centro de información online de medicamentos de la AEMPS	01178001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	431604
FR	Base de données publique des médicaments	69197468
GB	Medicines & Healthcare Products Regulatory Agency	43294
IE	Health Products Regulatory Authority	88403
IT	Agenzia del Farmaco	035710019
JP	医薬品医療機器総合機構	4291042M1022
LT	Valstybinė vaistų kontrolės tarnyba	1031005
NL	Z-Index G-Standaard, PRK	70610
PL	Rejestru Produktów Leczniczych	100133583
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66654001
US	FDA, National Drug Code	0187-5525, 0187-5526